A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED MULTICENTER STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE

Registry ID

EQ-100-02

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

EQUILLIUM, INC.

Start date

2022-07-19

Last update

2022-03-17

Conditions

• GRAFT VS HOST DISEASE

Related clinical trials

• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AXATILIMAB AND CORTICOSTEROIDS AS INITIAL TREATMENT FOR CHRONIC GRAFT VERSUS-HOST DISEASE
• AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424) STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT (LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT
• A PHASE 2, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AXATILIMAB IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE
• A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO EVALUATE EFFICACY AND SAFETY OF BELUMOSUDIL IN COMBINATION WITH CORTICOSTEROIDS VERSUS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH NEWLY DIAGNOSED CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
• A RANDOMIZED, OPEN-LABEL PHASE II CLINICAL TRIAL COMPARING DURABLE OVERALL RESPONSE RATE (DOR) AT 56 DAYS IN PATIENTS WITH STEROID-RESISTANT SEVERE ACUTE GVHD AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATED WITH DECIDUAL STROMAL CELLS (DSC) OR BEST AVAILABLE TREATMENT (BAT)
• A RANDOMIZED PILOT TRIAL COMPARING ANTI-THYMOCYTE GLOBULIN (ATG) WITH ATG PLUS POST TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) FOR PROPHYLAXIS AGAINST ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE (GVHD) IN MATCHED DONOR HEMATOPOIETIC CELL TRANSPLANTS (HCT)

View on source registry